Combination of Osimertinib and Chemotherapy Enhances Progression-Free Survival in EGFR-Mutated Non-Small Cell Lung Cancer
Combining osimertinib with chemotherapy significantly extends progression-free and overall survival in patients with EGFR-mutated non-small cell lung cancer, according to recent clinical trial results.
Recent findings presented at the 2025 World Conference on Lung Cancer highlight the benefits of combining osimertinib with chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. The COMPEL trial, a global double-blind study, evaluated patients who experienced non-central nervous system (CNS) disease progression on first-line osimertinib. Participants were randomized to receive either continued osimertinib alongside platinum-based chemotherapy or placebo with chemotherapy.
The study demonstrated that patients receiving osimertinib in combination with chemotherapy had a significantly longer progression-free survival (PFS), with a median of 8.4 months compared to 4.4 months in the placebo group. The hazard ratio for disease progression was 0.43, indicating a substantial reduction in risk. Additionally, overall survival was improved, with median overall survival reaching 15.9 months for the combination group versus 9.8 months for placebo plus chemotherapy.
Lead researcher Dr. Giulia Pasello from the Veneto Institute of Oncology explained that some tumor cells remain sensitive to continued osimertinib, supporting its use as a backbone treatment strategy in this setting. The combination therapy was well-tolerated, with safety profiles consistent with known effects of the individual agents. These promising results align with the findings from the FLAURA2 study, further emphasizing the potential of integrating osimertinib with chemotherapy for better patient outcomes.
This research underscores the importance of personalized treatment plans for patients with EGFR-mutated NSCLC post-progression, offering a new avenue to prolong disease control and improve survival rates.
Source: https://medicalxpress.com/news/2025-09-osimertinib-chemotherapy-free-survival-egfr.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
The Critical Role of Educating Children About Zoonotic Diseases and Safe Animal Interactions
Learn about the importance of teaching children safe interactions with animals to prevent zoonotic diseases and protect their health.
Continued Use of Antiseizure Medications During Pregnancy Despite Risks
A recent study highlights the ongoing use of antiseizure medications during pregnancy, with some drugs posing known or uncertain risks to fetal development. The research calls for better management and awareness, especially among socioeconomically disadvantaged populations.
Regeneron Acquires 23andMe Out of Bankruptcy for $256 Million
Regeneron Pharmaceuticals is set to acquire 23andMe out of bankruptcy for $256 million, gaining access to extensive genetic data that could accelerate biotech research. The deal follows 23andMe’s recent financial struggles and data breach impact.
Enhancing Hospital Discharge Summaries: A Call for Tailored Communication
A new study highlights the need for personalized and purpose-driven hospital discharge summaries to improve patient care and enhance communication between hospitals and GPs. Experts emphasize understanding GP perspectives for better discharge communication.